Clinical Trial ResultsPhase 2 results for VT1953 met primary and secondary endpoints in malignant fungating wounds and showed meaningful symptom improvements with a favorable safety profile, supporting advancement toward a pivotal study.
Financial PositionLow cash burn, a clean balance sheet with no debt or warrants, and available capital-raising capacity provide a runway into 2027 to support continued clinical development.
Market OpportunityMalignant fungating wounds represent a potential market opportunity of more than $1 billion with no FDA-approved therapies, creating significant commercial upside if VT1953 achieves approval.